News Sentiment

TSHA sentiment intelligence

Taysha Gene Therapies Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 65 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.96 Week of 17 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

88/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-6.0% over one week, -7.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Does Rett Trial Data and Share Offering Reshape the Bull Case for Taysha Gene Therapies (TSHA)?

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 88/100 classification
One-week reaction -6.0% Price reacting lower
Trend fit Trend active -7.2% over four weeks
Fair value 95.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 39
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 8
TradingView 8
Investing.com 6
GlobeNewswire 4
simplywall.st 3
MT Newswires 3
Simply Wall Street 3

Event Lens

What the news is about

Classified themes
Market update 50
Earnings 13
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 65
Stock Titan Direct company coverage

Taysha Gene Therapies (NASDAQ: TSHA) prices $200M equity raise with warrants

Taysha Gene Therapies (NASDAQ: TSHA) has priced an underwritten public offering to raise approximately $200 million in gross proceeds through the sale of common stock and pre-funded warrants. The company will sell 32,500,001 common shares at $6.00 each and pre-funded warrants for

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:10
Source
Stock Titan
Investing.com Direct company coverage

Taysha Gene Therapies prices $200M stock offering at $6 per share

Taysha Gene Therapies has priced an underwritten public offering of 32,500,001 shares of common stock at $6.00 per share, aiming to raise approximately $200 million. The company also offered pre-funded warrants and granted underwriters a 30-day option for additional shares. This

Tone
Positive 64/100
Event
Market update
Published
25 Jun 2026 03:03
Source
Investing.com